Literature DB >> 20013480

Dopaminergic modulation of the planning phase of skill acquisition in Parkinson's disease.

Brenda Hanna-Pladdy1, Kenneth M Heilman.   

Abstract

Patients with Parkinson's disease (PD) are often impaired when performing motor acts and in the acquisition of new motor skills. However, the role of dopamine in developing plans for skill acquisition is unclear. To assess the role of dopamine on the planning of actions, we tested 12 PD and 12 matched normal participants on two skill acquisition tasks matched for motor demands, but varying in requirements for planning. The participants with PD were tested on these tasks when they were on and off dopaminergic medications. To minimize influence of movement related deficits, the subjects used a computer track-pointer that generated the required straight lines when the subjects applied a slight force and clicked the track-pointer to initiate and terminate each line segment. The amount of time the track-pointer was deflected determined the line lengths, while clicking of the mouse determined the location of the line. The simple figure replication task only required the subjects to repeatedly generate lines of two sizes, while the complex figure replication task required subjects to generate lines of different sizes. Thus, this complex task demanded more anticipatory planning. Compared to controls, the subjects with PD were slower to learn the programs needed to produce these figures and produced figures with reduced amplitudes on both the simple and complex tasks. Dopamine treatment, however, only improved the speed of figure completion on the complex task, suggesting that dopamine is important in action planning.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013480      PMCID: PMC4354687          DOI: 10.1080/13554790903379609

Source DB:  PubMed          Journal:  Neurocase        ISSN: 1355-4794            Impact factor:   0.881


  36 in total

1.  Sequential arm movements in patients with Parkinson's disease, Huntington's disease and dystonia.

Authors:  R Agostino; A Berardelli; A Formica; N Accornero; M Manfredi
Journal:  Brain       Date:  1992-10       Impact factor: 13.501

Review 2.  Dopamine and cognitive function.

Authors:  Bernard Pillon; Virginie Czernecki; Bruno Dubois
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

3.  Functional imaging of sequence learning in Parkinson's disease.

Authors:  Maren Carbon; David Eidelberg
Journal:  J Neurol Sci       Date:  2006-06-05       Impact factor: 3.181

4.  Motor skill learning in Parkinson's disease.

Authors:  R Agostino; J N Sanes; M Hallett
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

5.  Hypometria in Parkinson's disease: automatic versus controlled processing.

Authors:  R M Oliveira; J M Gurd; P Nixon; J C Marshall; R E Passingham
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

6.  The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture.

Authors:  C D Marsden
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

7.  The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.

Authors:  Daphna Shohamy; Catherine E Myers; Steven Grossman; Jacob Sage; Mark A Gluck
Journal:  Behav Brain Res       Date:  2005-01-30       Impact factor: 3.332

8.  An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia.

Authors:  N Georgiou; R Iansek; J L Bradshaw; J G Phillips; J B Mattingley; J A Bradshaw
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

9.  Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function.

Authors:  F A Middleton; P L Strick
Journal:  Science       Date:  1994-10-21       Impact factor: 47.728

10.  Disturbance of sequential movements in patients with Parkinson's disease.

Authors:  R Benecke; J C Rothwell; J P Dick; B L Day; C D Marsden
Journal:  Brain       Date:  1987-04       Impact factor: 13.501

View more
  8 in total

1.  Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Authors:  Anne-Marie A Wills; Jordan J Elm; Rong Ye; Kelvin L Chou; Sotirios A Parashos; Robert A Hauser; Ivan Bodis-Wollner; Vanessa K Hinson; Chadwick W Christine; Jay S Schneider
Journal:  Parkinsonism Relat Disord       Date:  2016-10-08       Impact factor: 4.891

Review 2.  Influence of deep brain stimulation of the subthalamic nucleus on cognitive function in patients with Parkinson's disease.

Authors:  Bin Wu; Lu Han; Bo-Min Sun; Xiao-Wu Hu; Xiao-Ping Wang
Journal:  Neurosci Bull       Date:  2013-12-12       Impact factor: 5.203

3.  Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.

Authors:  Brenda Hanna-Pladdy; Rajesh Pahwa; Kelly E Lyons
Journal:  J Int Neuropsychol Soc       Date:  2015-04-29       Impact factor: 2.892

4.  Dopaminergic Basis of Spatial Deficits in Early Parkinson's Disease.

Authors:  B Hanna-Pladdy; R Pahwa; K E Lyons
Journal:  Cereb Cortex Commun       Date:  2021-06-24

Review 5.  Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.

Authors:  Michele Poletti; Ubaldo Bonuccelli
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

6.  Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.

Authors:  Amara Gul; Javed Yousaf
Journal:  Singapore Med J       Date:  2018-09-24       Impact factor: 1.858

7.  Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function.

Authors:  Penny A Macdonald; Oury Monchi
Journal:  Parkinsons Dis       Date:  2011-03-06

8.  Automatic Online Motor Control Is Intact in Parkinson's Disease With and Without Perceptual Awareness.

Authors:  Kate E Merritt; Ken N Seergobin; Daniel A Mendonça; Mary E Jenkins; Melvyn A Goodale; Penny A MacDonald
Journal:  eNeuro       Date:  2017-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.